AbbVie, Genmab Need Further Follow Up on Trial for Follicular Lymphoma Treatment
June 27 2023 - 7:48PM
Dow Jones News
By Paul Ziobro
AbbVie and Genmab said Tuesday that a clinical trial for a
bispecific antibody to treat a form of non-Hodgkin's lymphoma would
need further follow up, even after it saw positive topline
results.
The Epcore NHL-1 trial is evaluating the safety and preliminary
efficacy of epcoritamab, an investigational T-cell engaging
bispecific antibody administered subcutaneously, in patients with
follicular lymphoma.
The companies said topline results showed an overall response
rate that exceeded the protocol prespecified threshold for
efficacy, while the observed median duration of response wasn't
reached, which requires a longer follow up period.
AbbVie and Genmab said they would engage global regulatory
authorities to discuss next steps.
"We are encouraged by these topline results, which further
support the clinical profile of epcoritamab as a potential
therapeutic option for patients with relapsed or refractory
follicular lymphoma," said Dr. Mariana Cota Stirner, AbbVie's
therapeutic area head for hematology.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
June 27, 2023 19:33 ET (23:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024